Akari Therapeutics, the UK-incorporated oncology developer that restructured itself around a novel antibody-drug conjugate platform after its late-2024 reverse merger with Peak Bio, reported a second-quarter 2026 net loss of $4.8 million on June 30, a figure that looks mild only because the real damage was booked in the first quarter. The six-month loss of $19.3 million nearly quadrupled the $5.6 million loss of the prior-year first half, and the entire gap traces to $12.1 million of non-cash impairment charges on goodwill and in-process research and development assets written off in the first quarter after the company's market capitalization fell sharply. For the period ended June 30, 2026, the company held $7.7 million of cash, an accumulated deficit of $283.8 million, and an audit-flagging disclosure that cash funds operations only into December 2026.
The equity is best understood as a heavily diluted, cash-constrained option on a single preclinical asset, AKTX-101, a Trop-2-targeting antibody-drug conjugate built on a proprietary RNA-splicing payload that the company believes is more potent and more immune-stimulating than standard ADC chemotherapies. The market is not pricing this as a conventional clinical-stage biotech, because at roughly $13 million of market capitalization the equity is being valued almost entirely as a financing-and-liquidity story rather than as a future drug developer. Ordinary shares outstanding ballooned from 90.5 billion at December 31, 2025 to 140.0 billion at June 30, 2026 through warrant exercises and a May private placement, a 55% increase in six months that, together with a 1-for-80,000 ADS ratio change, compresses the per-share optics of any eventual value.
The load-bearing risk is simple and nameable: the company itself states its cash reaches only to December 2026, and it has no revenue, no approved products, and no committed external funding beyond an as-yet-untapped $25 million White Lion equity line whose registration only became effective in July 2026. The falsifiable clock is equally concrete. The next test is whether Akari can raise the next tranche of capital before the current $7.7 million is exhausted, and after that whether the AKTX-101 investigational-new-drug filing and the phase 1 first-in-human study actually begin on the company's stated mid-2027 timeline without another round of dilutive financing that further erodes the existing shareholder base.